Labour’s Budget Dilemma: Can they power up the UK’s life sciences sector?
David Boosey · Posted on: October 22nd 2024 · read
The Labour government’s upcoming Budget Day on 30th October has sparked speculation about its investment strategy, particularly regarding the UK’s life sciences sector.
As Chancellor Rachel Reeves prepares to outline her fiscal policy, the key question is whether Labour will take an aggressive approach to investment or exercise caution to avoid the mistakes of previous governments. While there was initial optimism in August, recent concerns about economic instability, fiscal deficits, and investor confidence have tempered expectations.
Despite this uncertainty, the life sciences sector remains a critical area for growth and innovation in the UK. To ensure the sector thrives in the coming years, a clear strategy is needed.
Below is a wish list of priorities Labour could adopt to strengthen life sciences, ensuring continued success in the sector.
- Enhancing Research and Development (R&D) Investment
The UK has a strong track record in health research and development, with significant investments in pharmaceutical R&D. In 2022, the sector saw investments amounting to £9.0 billion, representing 0.36% of the UK’s GDP1.- Increase R&D Funding: Allocate additional funds to support cutting-edge research and development, ensuring the UK remains at the forefront of medical innovation.
- Incentivise Private Investment: Introduce tax reliefs and incentives to encourage private sector investment in life sciences, fostering a collaborative environment between public and private entities.
- Streamlining Regulatory Processes
Post-Brexit regulatory changes have increased the compliance burden on life sciences companies, requiring separate approvals from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency2.- Simplify Approval Processes: Streamline regulatory requirements to reduce the time and cost associated with bringing new products to market.
- Harmonise Regulations: Align UK regulations more closely with international standards to facilitate easier market access and reduce duplication of efforts.
- Addressing Workforce Shortages
The life sciences sector faces a notable shortage of skilled professionals, which is exacerbated by the competitive global market for talent3.- Invest in Education and Training: Enhance STEM education and vocational training programs to build a robust pipeline of skilled professionals.
- Attract Global Talent: Implement policies that make the UK an attractive destination for international talent, including streamlined visa processes and competitive compensation packages.
- Boosting Clinical Trials and Patient Recruitment
Participation in industry clinical trials has declined significantly, impacting the UK’s competitiveness in global clinical research3.- Support Clinical Trials: Increase funding for clinical trials and create incentives for companies to conduct trials in the UK.
- Enhance Patient Recruitment: Develop initiatives to improve patient recruitment for clinical trials, ensuring diverse and representative participation.
- Strengthening Infrastructure
The life sciences sector requires specialised facilities, such as wet labs and manufacturing spaces, which are currently in short supply4.- Develop Specialised Facilities: Invest in the development of state-of-the-art research and manufacturing facilities to support the growth of life sciences companies.
- Public-Private Partnerships: Encourage collaboration between the NHS, academia, and industry to leverage resources and expertise.
- Supporting Innovation and Commercialisation
The UK has demonstrated its ability to innovate, as seen with the rapid development of the Oxford-AstraZeneca COVID-19 vaccine5. How can we ensure that we don’t stop that natural innovating zeal?- Foster Innovation: Provide grants and funding for innovative research projects and startups in the life sciences sector.
- Facilitate Commercialisation: Support the commercialisation of research by providing access to growth capital and reducing barriers to market entry.
- Improving Access to Global Markets
Expanding the global reach of UK life sciences companies is essential for their growth and success4.- Negotiate Trade Agreements: Secure favourable trade agreements that reduce barriers and promote international collaboration.
- Support Export Activities: Provide resources and support for companies looking to enter and compete in global markets.
Conclusion
As Labour approaches its first major fiscal test, the life sciences sector presents an opportunity to demonstrate its commitment to strategic investment in a sector that directly benefits public health. However, this will require navigating the complex political landscape, balancing bold investments with fiscal caution, and avoiding the missteps of past governments.
Investments in R&D, education, infrastructure, and streamlined regulations are essential for sustaining the sector’s growth. Labour has made promises to work in genuine partnership with industry leaders to strengthen the UK’s life sciences sector6. The question is whether it can deliver on these commitments on 30th October while maintaining fiscal discipline. If successful, Labour could secure both economic growth and public backing, as the life sciences sector has a more direct and visible impact on people’s lives than many other industries.
Stay updated with MHA
Ahead of the Autumn Budget, our VAT experts and industry specialists will be sharing their insights on the measures that would best support UK industries and individuals.
Stay updated on the latest developments right here on our dedicated Autumn Budget hub.
